Hepatitis B minor third-positive conversion represents the complete clearance of the hepatitis B virus by the body and the negative transformation of the surface antigen. There are three clinical methods that can make hepatitis B small triplet negative, as follows: First, pegylated interferon antiviral therapy, pegylated interferon injection once a week antiviral treatment, after 48 weeks of treatment about 11% of hepatitis B small triplet can turn negative. About 20-80% of the small triplets with surface antigen less than 1500 IU/ml before treatment can be turned negative. Second, nucleoside analogues taken orally and antiviral treatment for more than 4 years, the negative conversion rate of hepatitis B minor triple Yang is only 3%, which is only two percentage points higher than the natural conversion rate of minor triple Yang of 0.5%-1%. Third, medical practitioners try to combine or renew pegylated interferon after tenofovir or entecavir treatment, the chance of negative conversion will be improved. If the surface antigen level of SCT is <200, the chance of conversion is >50%. In general, the lower the surface antigen level, the higher the chance of conversion.